It will propose solutions for diagnosis, symptom monitoring and therapy
July 19, 2019 - It's called Brain Innovations and it's the first spin-off participated by Ucbm that joins the other six accredited by the University. Founded last April, it was born from the idea of the neurologist and PhD student Lazzaro di Biase which received a first seed investment from Zcube, Zambon Research Venture, thanks to its participation in the Open Accelerator Life Sciences competition.
The spin-off aims to solve three problems that patients with Parkinson's disease present today: low diagnostic accuracy (the error is estimated at 30 percent, with about 800 erroneous diagnoses each year); the absence of objective biomarkers for monitoring symptoms at home (multiple doctor visits are required, which increases costs); the suboptimal therapeutic management of fluctuations in patients' motor symptoms. Brain Innovations offers aid devices for diagnosis, symptom monitoring and administration of adequate therapy, with the long-term goal of offering solutions that can become the gold standard for the management of patients with Parkinson's. A disease that affects 10 million people worldwide and registers a new patient every 10 seconds and 183 new clinical studies every year.
In Europe and the United States alone, the management of the disease costs 19 million dollars, a figure expected to double in the next 10 years. A solution like the one proposed by Brain Innovations could reduce direct and indirect healthcare costs, leading to savings of 4,7 billion dollars in Europe and the US, and improve the quality of life of patients by opening new frontiers in personalized therapy.
